Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Lung diseases are disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. The term lung disease refers to many disorders affecting the lungs, such as asthmaCOPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure.


  • Track 1-1Allergic Asthma
  • Track 1-2 Diaphragmatic Breathing
  • Track 1-3Acute Respiratory Tract Infection
  • Track 1-4Acute Respiratory Distress Syndrome
  • Track 1-5Sinusitis

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus production and wheezing. It's caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD. The inflamed bronchial tubes produce a lot of mucus. This leads to coughing and difficulty breathing. It's characterized by a daily cough and mucus production

  • Track 2-1Chronic Bronchitis
  • Track 2-2Emphysema
  • Track 2-3Tripod Positioning
  • Track 2-4wheezing

Asthma is one of the chronic diseases involving the airway in the lungs. This airway is called bronchial tubes, allow air to come in and out of the lungs. In this asthma condition, your airway gets narrow and it will produce extra mucus. So that it can make breathing difficult and trigger coughing, wheezing and shortness of breath. it can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma can't be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that we need to track our signs and symptoms and adjust treatment as needed. Asthma causes difficulty in breathing that often results from an allergic reaction. when it comes to COPD both are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both result from gene-environment communications and both are typically characterized by mucus and bronchoconstriction

  • Track 3-1Allergy Induced Asthma
  • Track 3-2Diagnosis and Prevention
  • Track 3-3Breathing Difficulty
  • Track 3-4Stress

Lung cancer is a type of cancer that begins in the lungs. Your lungs are two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. The risk of lung cancer increases with the length of time and the number of cigarettes you've smoked.

  • Track 4-1Squamous cell carcinomas
  • Track 4-2Large cell carcinoma
  • Track 4-3Undifferentiated non-small cell lung cancer
  • Track 4-4Adenocarcinomas

Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease.

  • Track 5-1Active TB Disease
  • Track 5-2Miliary TB
  • Track 5-3Latent TB Infection
  • Track 5-4Chest pain

Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. IPF is a form of interstitial lung disease, primarily involving the interstitial (the tissue and space around the air sacs of the lungs), and not directly affecting the airways or blood vessels. There are many other kinds of interstitial lung disease that can also cause inflammation and/or fibrosis, and these are treated differently.

  • Track 6-1Idiopathic nonspecific interstitial pneumonia
  • Track 6-2Familial idiopathic pulmonary fibrosis
  • Track 6-3Cryptogenic organizing pneumonia
  • Track 6-4Sarcoidosis

Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. These secreted fluids are normally thin and slippery. But in people with cystic fibrosis, a defective gene causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas.

  • Track 7-1Coughing up blood
  • Track 7-2Chronic fatigue
  • Track 7-3Mutations

Stage 1 or intermittent asthma: This group of children has symptoms no more than two times a week, do not have problems in-between flare-ups, and only have short flare-ups from a few hours to a few days. Night-time symptoms occur less than two times a month.

Stage 2 or mild persistent: This group of children has symptoms more than two times a week, but not daily, and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than two times a month, but no more than once per week.

Stage 3 or moderate persistent: This group of children has symptoms every day, use their rescue medication every day and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than one time a week.

Stage 4 or severe persistent: This group of children has symptoms multiple times per day, have a decrease in their physical activity and have frequent flare-ups. Night-time symptoms occur frequently.

  • Track 8-1Mild Intermittent Asthma
  • Track 8-2Mild Persistent Asthma
  • Track 8-3Moderate Persistent Asthma
  • Track 8-4Severe Persistent Asthma

Bronchial asthma is a resistant interceded issue described by reversible aviation route irritation, mucous discharge, and a variable stream of air deterring with aviation route hyperresponsiveness. Allergen presentation prompts the initiation of different cells of the framework, of those dendritic cells and Th2 lymphocytes are of principal significance. Even though the epithelium was at first considered to work independently as a physical boundary, it is as of now detectable that it assumes a focal part in the Th2-cell refinement process because of its possibility to initiate dendritic cells. Pole cells and eosinophil were at first accepted to assume a key part in driving the aviation route irritation related to asthma, new information infer that T partner cells are basic. It has been demonstrated that hypersensitive asthma is related with expanded TH2 cytokine generation that causes initiation of eosinophils and T-cells and creation of chemokine by aspiratory fibroblasts.

  • Track 9-1Immune Disorder
  • Track 9-2Airway Inflammation
  • Track 9-3Allergic Asthma
  • Track 9-4Immunopathogenesis

Pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Basically, it has characterized, inflammation in the peripheral airspaces in different stages of disease severity. The first is a Protease-Antiprotease imbalance, which has been linked to the pathogenesis of emphysema. The second process, oxidative stress, has a role in many of the pathogenic processes of chronic obstructive pulmonary disease and may be one mechanism that enhances the inflammatory response.

  • Track 10-1Tachypnea
  • Track 10-2Respiratory Distress
  • Track 10-3Small Airway Disease
  • Track 10-4Cough

Lung Inflammation is characterized by COPD, which intensifies with disease progression Lung or bronchial biopsies and induced sputum have shown evidence of lung inflammation in all cigarette smokers. However, it appears that an enhanced or abnormal inflammatory response to inhaled particles or gases, beyond the normal protective inflammatory response in the lungs, is a characteristic feature of COPD and has the potential to produce lung injury.

  • Track 11-1Acute Lung Inflammation
  • Track 11-2Chronic Effects of Smoking
  • Track 11-3Autoimmunity
  • Track 11-4Lung Microbiome

Chronic obstructive pulmonary disease (COPD) is responsible for early mortality, high death rates and significant cost to health systems. Active smoking remains the main risk factor, but other factors are becoming better known, such as occupational factors, infections and the role of air pollution. Prevalence of COPD varies according to the country, age and sex. This disease is also associated with significant comorbidities. COPD is a disorder that includes various phenotypes, the continuum of which remains under debate. The major challenge in the coming years will be to prevent the onset of smoking along with early detection of the disease in the general population. This may represent deterioration in the patient's premorbid condition such that hypoxemia worsens and hypercapnia develops during a relatively trivial respiratory tract infection, which may be viral or bacterial.

  • Track 12-1Smoking
  • Track 12-2Air Pollution
  • Track 12-3Occupational Factors
  • Track 12-4Short of Breath

Numerous cohort studies have demonstrated an increased risk of cardiovascular-related mortality in patients with COPD. Interestingly, this association is often seen in mild and moderate COPD. It is both disappointing and depressing that both the management of cardiovascular disease and the assessment of risk in patients with COPD is repeatedly suboptimal. The amino acids desmosine and isodesmosine are involved in elastin cross-linking, have utility as a measure of elastin breakdown, and may have value in determining both risk of cardiovascular disease and a link to a possible causal mechanism. The detection of increased arterial stiffness in patients with COPD furthers leads to the understanding of the possible mechanism for cardiovascular disease in COPD.

  • Track 13-1Causes of Cardiovascular Diseases
  • Track 13-2Prevention and Management
  • Track 13-3Drugs for Indication and Prevention
  • Track 13-4Public Health Awareness- Prevention of Smoking

Pulmonary therapies are known as exercises and treatments designed to help patients maintain and recover lung function, such as with cystic fibrosis and after surgery. Also used for COPD and asthma.
Respiratory Therapy is a specialized healthcare training in pulmonary medicine in order to work therapeutically with people suffering from pulmonary disease.


  • Track 14-1Pulmonary Rehabilitation
  • Track 14-2Outpatient Clinical Practice
  • Track 14-3Home Health Care
  • Track 14-4Intensive Care and Operating Room

Patients who struggle with advanced COPD and acute or chronic respiratory failure are at high risk for death. Beyond pharmacological treatment, supplemental oxygen and mechanical ventilation are major treatment options. If your lungs fail to do their job passing oxygen into your bloodstream and removing carbon dioxide. It can be a complication of chronic obstructive pulmonary disease (COPD).In respiratory failure, the gas exchange doesn't work the way it's supposed to work, and the cells in your body start to suffer from a lack of oxygen, too much carbon dioxide, or both. Too much carbon dioxide can disrupt the acid-base balance in the body, which can lead to respiratory failure.

  • Track 15-1Bronchial Hyper responsiveness
  • Track 15-2Increased Tactile Fremitus
  • Track 15-3Pulmonary Emphysema
  • Track 15-4Prolonged Chronic Cough

The Bronchoconstriction in COPD will take place when the autonomic nervous system regulates the contraction and relaxation of smooth muscle thus controlling the diameter of the bronchioles, the rate of breathing and regulating the rate of airflow. The autonomic nervous system is further divided into the sympathetic nervous system and parasympathetic nervous system. In the respiratory system, the sympathetic and parasympathetic systems have opposing actions. Stimulation of the sympathetic nervous system causes the smooth muscle of the bronchi and bronchioles to relax, causing bronchodilation, whereas stimulation of the parasympathetic nervous system causes smooth muscle to contract, leading to bronchoconstriction Bronchodilators improve the airflow limitation observed in patients with COPD by producing airway smooth muscle relaxation, although beta ‘agonists and anticholinergics achieve this effect through different mechanisms.  

  • Track 16-1Gas Exchange Abnormalities
  • Track 16-2Pulmonary Hypertension
  • Track 16-3Air Trapping
  • Track 16-4Ciliary Dysfunction

Basically, the pathophysiology of COPD is rapidly unveiling. There will be some physiological change which eventually impacts the quality of life and survival in the natural progress of COPD when The pathological consequences of the COPD inflammation induce a series of physiological changes. Fibrotic remodelling of the airways results in fixed airway narrowing causing increased airway resistance which does not fully revert even with bronchodilators. Emphysema also reduces lung elastic recoil pressure which leads to a reduced driving pressure for expiratory flow through narrowed and poorly supported airways in which airflow resistance is significantly increased.

  • Track 17-1Dyspnea
  • Track 17-2Antitrypsin Deficiency
  • Track 17-3Bronchial Hyper reactivity
  • Track 17-4Tachypnea

Medication always plays a key part in how well you control your condition. There are two principle kinds of treatment, each designed for a objective. Controller pharmaceuticals are the most essential since they avert asthma assaults. When you utilize these medications, your aviation routes are less aggravated and more averse to respond to triggers. If you need to utilize a safeguard drug more than two times per week, your asthma isn't very much controlled. The correct pharmaceutical ought to enable you to carry on with a functioning and ordinary life. On the off chance that your asthma side effects aren't controlled, request that your specialist enable you to locate an alternate treatment that works better.

  • Track 18-1Controller Medications
  • Track 18-2Inhalers, Nebulizers and Pills
  • Track 18-3Long-Term Control Medications
  • Track 18-4Asthma Medication Guidelines

Treatment is depending upon the type of disease and stages. Either it will be treated in the surgical or non-surgical method, when it comes to the surgical process some of the treatments are lung transplant, Lung volume reduction surgery, and Bullectomy, another type is known a non-surgical process here, Airway clearance therapy, Pulmonary Rehabilitation, Vaccines, and antibiotics.

  • Track 19-1Lung Volume Reduction Surgery
  • Track 19-2Airway Clearance Therapy
  • Track 19-3Pulmonary Rehabilitation
  • Track 19-4Lung Transplant
  • Track 19-5Oxygen Therapy
  • Track 19-6Vaccines

Patients with Chronic Obstructive Pulmonary Disease have to acquire and the skills they need to carry out disease, Self-management in chronic obstructive pulmonary disease, centring on an action plan for the exacerbation and enhanced communication between the patient and healthcare providers, makes good clinical sense. Only two demonstrated reductions in health care utilization and one had to be discontinued prematurely because of increased mortality. Breathing techniques that can help you get the air you need without working so hard to breathe, Our primary objective was to assess the long-term effects of two different modes of COPD disease management comprehensive self-management and routine monitoring on quality of life in COPD patients in general practice. As secondary objectives, we assessed the effects on frequency and patients’ management of exacerbations and on self-efficacy. A systematic review of self-management in COPD concluded that it reduces hospital admissions and has no detrimental effects.

  • Track 20-1Medication
  • Track 20-2Health Care Utilization
  • Track 20-3Cardiac Workout
  • Track 20-4Healthy Diet
  • Track 20-5Diaphragmatic Breathing

Nowadays patients with Respiratory diseases use various devices, which help the removal of mucus from the Airways and the improvement of pulmonary function. Routine respiratory organ performs, and metabolism muscle testing is suggested in youngsters with Neuromuscular Disease, however, these tests are supported non-invasive voluntary manoeuvres, like the measuring of respiratory organ volumes and supreme static pressures, which young youngsters might not forever be able to perform. Basically, before the treatment Observation metabolism muscles in youngsters with NMD might improve understanding of the explanation of NMD and therefore the analysis of sickness severity. Nowadays devices seem to increase patients' compliance with daily treatment, because they present many benefits, as an independent application, full control of therapy and easy use.

  • Track 21-1Lung Transplantation in Cystic Fibrosis
  • Track 21-2Positive Airway Pressure Therapy
  • Track 21-3Physiotherapy
  • Track 21-4Physical Examination

The Division of Paediatric Pulmonary and Sleep Medicine provides comprehensive care to infants, children, and adults with a full spectrum of respiratory disorders. Care is guided in all age groups by the routine measurements of lung function. This department also provides the teaching and training in Paediatric pulmonology for diagnosing and treating the various disorders. mostly various pulmonary disorders are treated with the help of ventilation machines and medications.

  • Track 22-1Bronchopulmonary Dysplasia
  • Track 22-2Primary Ciliary Dyskinesia
  • Track 22-3Bronchopulmonary Dysplasia
  • Track 22-4Bronchiolitis Obliterans